6,900 Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Acquired by Pamalican Asset Management Ltd

Pamalican Asset Management Ltd acquired a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the 4th quarter, HoldingsChannel reports. The institutional investor acquired 6,900 shares of the biopharmaceutical company’s stock, valued at approximately $4,915,000. Regeneron Pharmaceuticals accounts for about 2.2% of Pamalican Asset Management Ltd’s investment portfolio, making the stock its 16th biggest holding.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Willner & Heller LLC lifted its position in Regeneron Pharmaceuticals by 3.9% during the 4th quarter. Willner & Heller LLC now owns 399 shares of the biopharmaceutical company’s stock worth $284,000 after buying an additional 15 shares in the last quarter. OLD Second National Bank of Aurora boosted its position in Regeneron Pharmaceuticals by 0.5% during the fourth quarter. OLD Second National Bank of Aurora now owns 2,843 shares of the biopharmaceutical company’s stock valued at $2,025,000 after purchasing an additional 15 shares during the last quarter. Rakuten Securities Inc. increased its position in shares of Regeneron Pharmaceuticals by 62.5% during the 4th quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 15 shares during the last quarter. TD Private Client Wealth LLC raised its stake in shares of Regeneron Pharmaceuticals by 9.6% during the 4th quarter. TD Private Client Wealth LLC now owns 171 shares of the biopharmaceutical company’s stock worth $122,000 after purchasing an additional 15 shares in the last quarter. Finally, Manchester Capital Management LLC grew its stake in shares of Regeneron Pharmaceuticals by 12.6% in the fourth quarter. Manchester Capital Management LLC now owns 161 shares of the biopharmaceutical company’s stock valued at $115,000 after buying an additional 18 shares in the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Trading Down 2.4 %

Shares of Regeneron Pharmaceuticals stock opened at $610.64 on Friday. The firm’s 50-day moving average price is $678.75 and its two-hundred day moving average price is $785.70. The company has a market capitalization of $66.76 billion, a price-to-earnings ratio of 15.95, a PEG ratio of 2.34 and a beta of 0.27. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 12-month low of $604.40 and a 12-month high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The business had revenue of $3.79 billion for the quarter, compared to analysts’ expectations of $3.76 billion. During the same period last year, the firm posted $11.86 earnings per share. The firm’s quarterly revenue was up 10.3% compared to the same quarter last year. On average, analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th were issued a dividend of $0.88 per share. The ex-dividend date of this dividend was Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.58%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 2.30%.

Analysts Set New Price Targets

A number of brokerages have commented on REGN. Robert W. Baird cut their price target on shares of Regeneron Pharmaceuticals from $940.00 to $759.00 and set a “neutral” rating for the company in a research note on Wednesday, February 5th. Bank of America reiterated an “underperform” rating and set a $565.00 price target on shares of Regeneron Pharmaceuticals in a report on Tuesday, December 10th. TD Cowen lowered their price target on Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a “buy” rating on the stock in a research report on Tuesday, February 4th. JPMorgan Chase & Co. decreased their price target on shares of Regeneron Pharmaceuticals from $1,100.00 to $1,000.00 and set an “overweight” rating on the stock in a research note on Monday. Finally, Leerink Partnrs upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, February 5th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have assigned a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $966.88.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.